Plinabulin is being evaluated for the prevention of chemo-induced neutropenia (CIN) and is currently in two global multi-center clinical trials aiming for a broad indication of prevention of all chemo-induced neutropenia in all cancer type. We believe that Plinabulin’s clinical profile, such as its potential for lower bone pain and its ability to be administered 30 minutes to one hour after chemotherapy (which preserves neutrophils), as well as its potential anti-cancer effects, may make it an attractive alternative to existing therapies for the treatment of CIN.
The first trial, Study 105, is a Phase 2/3 trial of Plinabulin in combination with a standard regimen of docetaxel in approximately 200 advanced breast cancer, hormone refractory prostate cancer and advanced NSCLC patients in the U.S, China, Russia, Hungary and the Ukraine with solid tumors. The Phase 2 portion of this study is now completed and the Phase 3 portion of this study is underway.
The second trial, Study 106, is a Phase 2/3 trial of Plinabulin in combination with a myelosuppressive chemotherapeutic regimen composed of three agents, Taxotere (docetaxel), Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), or TAC, in approximately 200 patients in the U.S., China, Russia, Hungary and the Ukraine with solid tumors. The Phase 2 portion of this study is underway.
For details of these two trials, please visit the below websites.